The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Valeev V.V.

I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg, Russia

Kovalenko A.L.

Direktsiia po nauke OOO "NTFF "Polisan", Sankt-Peterburg

Trashkov A.P.

St. Petersburg State Pediatric Medical University, St. Petersburg

Endothelium protection is a potential prevention strategy for anthracycline-induced cardiomyopathy

Authors:

Valeev V.V., Kovalenko A.L., Trashkov A.P.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2019;8(4): 308‑315

DOI: 10.17116/onkolog20198041308

Read: 1270 times

Contact the author
Table of contents

ENDOTHELIUM PROTECTION IS A POTENTIAL PREVENTION STRATEGY FOR ANTHRACYCLINE-INDUCED CARDIOMYOPATHY
ENDOTHELIUM PROTECTION IS A POTENTIAL PREVENTION STRATEGY FOR ANTHRACYCLINE-INDUCED CARDIOMYOPATHY

To cite this article:

Valeev VV, Kovalenko AL, Trashkov AP. Endothelium protection is a potential prevention strategy for anthracycline-induced cardiomyopathy. P.A. Herzen Journal of Oncology. 2019;8(4):308‑315. (In Russ.)
https://doi.org/10.17116/onkolog20198041308

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

The review considers current views on the pathogenesis of anthracycline-induced cardiomyopathy in the light of the latest ideas about the molecular mechanisms of its development. Attention is paid to the possible role of nitric oxide and nitric oxide synthases in the development of anthracycline-induced cardiotoxicity. The results of clinical and experimental studies of the efficiency of various cardioprotective therapies, including those aimed at restoring the functional activity of the endothelium, are presented.

Keywords:

anthracyclines
cardiotoxicity
cardiomyopathy
heart failure
endothelium
nitric oxide
NOS
L-arginine sodium succinate

Authors:

Valeev V.V.

I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg, Russia

Kovalenko A.L.

Direktsiia po nauke OOO "NTFF "Polisan", Sankt-Peterburg

Trashkov A.P.

St. Petersburg State Pediatric Medical University, St. Petersburg

Close metadata

References:

  1. Grenier M, Lipshultz S. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998;25(4):72-85.
  2. Snegovoy AV, Vitsenya MV, Kopp MV, Larionova VB. Practical recommendations for the correction of cardiovascular toxicity induced by chemotherapy and targeted drugs. Zlokachestvennye opukholi. 2016;4(Suppl. 2):418-427. (In Russ.)
  3. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53(2):105-113. https://doi.org/10.1016/j.pcad.2010.06.007
  4. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, et al.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-2801. https://doi.org/10.1093/eurheartj/ehw211
  5. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-2879.
  6. Rickard J, Kumbhani DJ, Baranowski B, Martin DO, Tang WH, Wilkoff BL. Usefulness of cardiac resynchronization therapy in patients with adriamycin-induced cardiomyopathy. Am J Cardiol. 2010;105(4):522-526.
  7. Gendlin GE, Emelina EI, Nikitin IG, Vasyuk YuA. Modern view on cardiotoxicity of chemotherapeutics in oncology including anthracyclines. Rossiiskiy kardiologicheskiy zhurnal. 2017;(3):145-154. (In Russ.) https://doi.org/10.15829/1560-4071-2017-3-145-154
  8. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077-1084.
  9. Bielack SS, Erttmann R, Winkler K, Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol. 1989;25(5):873-882.
  10. Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Henkel JM, Franco VI, Cushman LL, et al.; Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics. 2012;130(6):1003-1011. https://doi.org/10.1542/peds.2012-0727
  11. Minotti G, Cairo G, Monti E. Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J. 1999;13(2):199-212.
  12. Horenstein MS, Vander Heide RS, L’Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab. 2000;71(1-2):436-444.
  13. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57(7):727-741.
  14. Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J. Pathol. 2005;207(4):436-444.
  15. Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61(1):154-171.
  16. Luu AZ, Chowdhury B, Al-Omran M, Teoh H, Hess DA, Verma S. Role of endothelium in doxorubicin-induced cardiomyopathy. JACC Basic Transl Sci. 2018;3(6):861-870. https://doi.org/10.1016/j.jacbts.2018.06.005
  17. Mukhopadhyay P, Rajesh M, Bátkai S, Kashiwaya Y, Haskó G, Liaudet L, Szabó C, Pacher P. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol. 2009;296(5):1466-1483. https://doi.org/10.1152/ajpheart.00795.2008
  18. Mihm MJ, Yu F, Weinstein DM, Reiser PJ, Bauer JA. Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase. Br J Pharmacol. 2002;135(3):581-588.
  19. Nony P, Guastalla JP, Rebattu P, Landais P, Lievre M, Bontemps L, Itti R, Beaune J, Andre-Fouet X, Janier M. In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy. Cancer Chemother Pharmacol. 2000;45(5):375-380.
  20. Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med. 2003;35(11):1469-1479.
  21. Dresdale AR, Barr LH, Bonow RO, Mathisen DJ, Myers CE, Schwartz DE, d’Angelo T, Rosenberg SA. Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. Am J Clin Oncol. 1982;5(6):657-663.
  22. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63-75. https://doi.org/10.1007/s10557-016-6711-0
  23. Hevener K, Verstak TA, Lutat KE, Riggsbee DL, Mooney JW. Recent developments in topoisomerase-targeted cancer chemotherapy. Acta Pharm Sin B. 2018;8(6):844-861. https://doi.org/10.1016/j.apsb.2018.07.008
  24. Vejpongsa P, Yeh ET. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther. 2014;95(1):45-52. https://doi.org/10.1038/clpt.2013.201
  25. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen: role of reactive oxygen and nitrogen species. J Biol Chem. 2000;275(43):33585-33592.
  26. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol. 1999;57(7):727-741.
  27. Wolf MB, Baynes JW. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta. 2006;1760(2):267-271.
  28. Wallez Y, Huber P. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim Biophys Acta. 2008;1778(3):794-809.
  29. Narmoneva DA, Vukmirovic R, Davis ME, Kamm RD, Lee RT. Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration. Circulation. 2004;110(8):962-968.
  30. Lim SL, Lam CS, Segers VF, Brutsaert DL, De Keulenaer GW. Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. Eur Heart J. 2015;36(31):2050-2060.
  31. Wilkinson EL, Sidaway JE, Cross MJ. Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability. Biol Open. 2016;5(10):1362-1370. https://doi.org/10.1242/bio.020362
  32. Fernandez-Fernandez A, Carvajal DA, Lei T, McGoron AJ. Chemotherapy-induced changes in cardiac capillary permeability measured by fluorescent multiple indicator dilution. Ann Biomed Eng. 2014;42(12):2405-2415. https://doi.org/10.1007/s10439-014-1110-9
  33. Keltai K, Cervenak L, Mako V, Doleschall Z, Zsary A, Karadi I. Doxorubicin selectively suppresses mRNA expression and production of endothelin-1 in endothelial cells. Vasc Pharmacol. 2010;53:209-214. https://doi.org/10.1016/j.vph.2010.08.001
  34. Vásquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA Jr, Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 1997;36(38):11293-11297.
  35. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938-945. https://doi.org/10.1016/j.jacc.2014.06.1167
  36. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF. Topoisomerase II beta mediated DNA double-strand breaks:implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839-8846.
  37. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007;25(5):493-500.
  38. Kraft J, Grille W, Appelt M, Hossfeld DK, Eichelbaum M, Koslowski B, Quabeck K, Kuse R, Büchner T, Hiddemann W. Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial. Haematol Blood Transfus. 1990;33:566-570.
  39. Gallegos-Castorena S, Martinez-Avalos A, Mohar-Betancourt A, Guerrero-Avendano G, Zapata-Tarres M, Medina-Sanson A. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr Hematol Oncol. 2007;24(6):403-408.
  40. Iarussi D, Auricchio U, Agretto A, Murano A, GiulianoM, Casale F. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Asp Med. 1994;15:207-212.
  41. Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, Meriç M, Ağaç MT. Efficiency of atorvastatin in the protection of anthracyclineinduced cardiomyopathy. J Am Coll Cardiol. 2011;58(9):988-989. https://doi.org/10.1016/j.jacc.2011.05.025
  42. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzó M, Esteve J. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355-2362. https://doi.org/10.1016/j.jacc.2013.02.072
  43. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671-1680.
  44. Deng S, Kruger A, Schmidt A, Metzger A, Yan T, Gödtel-Armbrust U, Hasenfuss G, Brunner F, Wojnowski L. Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice. Naunyn Schmiedebergs Arch Pharmacol. 2009;380(1):25-34. https://doi.org/10.1007/s00210-009-0407-y
  45. Cole MP, Chaiswing L, Oberley TD, Edelmann SE, Piascik MT, Lin SM, Kiningham KK, St Clair DK. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. Cardiovasc Res. 2006;69(1):186-197.
  46. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, Deb A, Szabo E, Ungvari Z, Wolin MS, Groves JT, Szabo C. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation. 2003;107(6):896-904.
  47. Neilan TG, Blake SL, Ichinose F, Raher MJ, Buys ES, Jassal DS, Furutani E, Perez-Sanz TM, Graveline A, Janssens SP, Picard MH, Scherrer-Crosbie M, Bloch KD. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation. 2007;116(5):506-514.
  48. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, Hobai IA, Lemmon CA, Burnett AL, O’Rourke B, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature. 2002;416(6878):337-339.
  49. Zhu SG, Kukreja RC, Das A, Chen Q, Lesnefsky EJ, Xi L. Dietary nitrate supplementation protects against Doxorubicin-induced cardiomyopathy by improving mitochondrial function. J Am Coll Cardiol. 2011;57(21):2181-2189. https://doi.org/10.1016/j.jacc.2011.01.024
  50. de Nigris F, Rienzo M, Schiano C, Fiorito C, Casamassimi A, Napoli C. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. Eur J Cancer. 2008;44(3):334-340. https://doi.org/10.1016/j.ejca.2007.12.010
  51. Skrypnyk I, Maslova G, Lymanets T, Gusachenko I. L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia. Exp Oncol. 2017;39(4):308-311.
  52. Valeev VV, Trashkov AP, Kovalenko AL, Petrov AYu, Vasil’ev AG. Sodium-L-argininesuccinate – anew vasodilating medicine for the treatment and prophylaxis of doxorubicin-induced cardiotoxicity. Patologicheskaya fiziologiya i eksperimental’naya terapiya. 2016;60(4):52-57. (In Russ.)
  53. Valeev VV, Trashkov AP, Kovalenko AL, Petrov AYu, Vasil’ev AG. Prevention and correction of anthracycline-induced angiopathy: an experimental study. Onkologiya. Zhurnal im. P.A. Gertsena. 2016;5(6):31-34. (In Russ.) https://doi.org/10.17116/onkolog20165631-34
  54. Trashkov AP, Vasil’ev AG, Kovalenko AL, Petrov AYu, Valeev VV. Influence ofangioprotector drugs on the efficacy of cytostatic therapy (experimental study). Eksperimental’naya i klinicheskaya farmakologiya. 2016;79(2):34-39. (In Russ.)
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.